Ingevity (NYSE:NGVT – Get Free Report) issued an update on its FY 2026 earnings guidance on Wednesday morning. The company provided EPS guidance of 4.800-5.20 for the period, compared to the consensus EPS estimate of 4.760. The company issued revenue guidance of $1.1 billion-$1.2 billion, compared to the consensus revenue estimate of $1.2 billion.
Analysts Set New Price Targets
Several research analysts have commented on the stock. Zacks Research upgraded shares of Ingevity to a “hold” rating in a research report on Tuesday, December 16th. Weiss Ratings reissued a “sell (d-)” rating on shares of Ingevity in a report on Thursday, January 22nd. Wall Street Zen cut Ingevity from a “strong-buy” rating to a “buy” rating in a research report on Saturday. Wells Fargo & Company boosted their price target on Ingevity from $60.00 to $65.00 and gave the stock an “equal weight” rating in a research report on Wednesday, January 28th. Finally, BMO Capital Markets increased their price target on Ingevity from $64.00 to $70.00 and gave the stock an “outperform” rating in a research note on Wednesday, December 10th. One research analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $67.50.
View Our Latest Research Report on Ingevity
Ingevity Price Performance
Ingevity (NYSE:NGVT – Get Free Report) last issued its quarterly earnings results on Wednesday, February 25th. The company reported $0.58 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.74 by ($0.16). Ingevity had a negative net margin of 5.14% and a positive return on equity of 103.69%. Ingevity has set its FY 2026 guidance at 4.800-5.20 EPS. Sell-side analysts predict that Ingevity will post 4.45 EPS for the current year.
Institutional Investors Weigh In On Ingevity
Institutional investors and hedge funds have recently bought and sold shares of the business. Global Retirement Partners LLC acquired a new position in shares of Ingevity in the 4th quarter worth approximately $27,000. Meeder Asset Management Inc. acquired a new stake in Ingevity during the fourth quarter valued at approximately $33,000. Geneos Wealth Management Inc. boosted its holdings in Ingevity by 85.8% during the second quarter. Geneos Wealth Management Inc. now owns 838 shares of the company’s stock worth $36,000 after buying an additional 387 shares in the last quarter. Headlands Technologies LLC acquired a new position in Ingevity in the second quarter worth approximately $46,000. Finally, Kestra Advisory Services LLC bought a new position in shares of Ingevity in the fourth quarter valued at $47,000. 91.59% of the stock is owned by institutional investors and hedge funds.
About Ingevity
Ingevity Corporation, traded as NGVT, is a specialty chemicals and performance materials company headquartered in North Charleston, South Carolina. The company operates two primary business units: Performance Chemicals and Performance Materials. The Performance Chemicals segment produces and markets specialty chemicals derived largely from wood and other natural feedstocks, including rosin acids, tall oil fatty acids and esters, as well as specialty petroleum resins. These products serve a broad range of industries, including paper, adhesives, coatings, oilfield drilling and consumer goods.
The Performance Materials segment develops and manufactures activated carbon products and composites for applications such as automotive emissions control, industrial air and water purification, and spill containment.
Featured Stories
- Five stocks we like better than Ingevity
- The gold chart Wall Street is terrified of…
- America’s 1776 happening again
- This makes me furious
- Buy this Gold Stock Before May 2026
- What a Former CIA Agent Knows About the Coming Collapse
Receive News & Ratings for Ingevity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ingevity and related companies with MarketBeat.com's FREE daily email newsletter.
